KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Income from Continuing Operations: 2010-2025

Historic Income from Continuing Operations for TherapeuticsMD (TXMD) over the last 15 years, with Sep 2025 value amounting to $50,000.

  • TherapeuticsMD's Income from Continuing Operations rose 108.82% to $50,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $42,000, marking a year-over-year increase of 101.05%. This contributed to the annual value of -$2.3 million for FY2024, which is 69.97% up from last year.
  • According to the latest figures from Q3 2025, TherapeuticsMD's Income from Continuing Operations is $50,000, which was down 90.83% from $545,000 recorded in Q2 2025.
  • Over the past 5 years, TherapeuticsMD's Income from Continuing Operations peaked at $50.1 million during Q4 2021, and registered a low of -$47.4 million during Q3 2021.
  • In the last 3 years, TherapeuticsMD's Income from Continuing Operations had a median value of -$809,000 in 2024 and averaged -$920,545.
  • Per our database at Business Quant, TherapeuticsMD's Income from Continuing Operations spiked by 219.16% in 2021 and then tumbled by 103.27% in 2023.
  • Over the past 5 years, TherapeuticsMD's Income from Continuing Operations (Quarterly) stood at $50.1 million in 2021, then declined by 3.38% to $48.5 million in 2022, then slumped by 103.27% to -$1.6 million in 2023, then skyrocketed by 105.24% to $83,000 in 2024, then soared by 108.82% to $50,000 in 2025.
  • Its Income from Continuing Operations was $50,000 in Q3 2025, compared to $545,000 in Q2 2025 and -$636,000 in Q1 2025.